Drug Trial Radar · NCT06500299
Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
Last checked: Nov 19, 2026Latest source record: Jul 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
180
Planned (sponsor's estimate)
Start
Jul 15, 2024
Primary completion
Oct 30, 2024
Study completion Nov 30, 2024
Sponsor
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults.
Conditions
- Overweight and Obesity
Interventions
HDM1002 100 mg QDDrug
HDM1002 tablets 100mg daily, 12weeks
HDM1002 200 mg QD 12weeksDrug
HDM1002 tablets 200mg daily, 12weeks
HDM1002 400 mg QD 12weeksDrug
HDM1002 tablets 400mg daily, 12weeks
PlaceboDrug
Matching placebo will be provided
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change From Baseline in Body Weight at Week 12Time frame: Baseline, Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.